Philippe Arnaud
Institut Gustave Roussy
6 Papers
44 Citations
Philippe Arnaud is an academic researcher from Institut Gustave Roussy. The author has contributed to research in topics: Transplantation & Hematopoietic stem cell transplantation. The author has an hindex of 5, co-authored 6 publications.
Chat about Author
Papers
Allogeneic Hematopoietic Stem-Cell Transplantation After Nonmyeloablative Preparative Regimens: Impact of Pretransplantation and Posttransplantation Factors on Outcome
Mauricette Michallet,Karin Bilger,Frédéric Garban,Michel Attal,Anne Huyn,Didier Blaise,Noel Milpied,Philippe Moreau,Pierre Bordigoni,M. Kuentz,A Sadoun,Jean-Yves Cahn,Gérard Socié,Xavier Thomas,Philippe Arnaud,Nicole Raus,Véronique Lhéritier,Arnaud Pigneux,Jean-Michel Boiron +18 more
TL;DR: This series shows encouraging results from nonmyeloablative conditioning regimens before allotransplantation and demonstrates the impact of some pre- and posttransplantation factors on outcome after transplantation.
93
High survival rate with the LMT-89 regimen in lymphoblastic lymphoma (LL), but not in T-cell acute lymphoblastic leukemia (T-ALL)
E. Jabbour,Serge Koscielny,Catherine Sebban,N. Peslin,Catherine Patte,T Gargi,P Biron,Christophe Fermé,J. H. Bourhis,J. M. Vantelon,Philippe Arnaud,Vincent Ribrag +11 more
TL;DR: This LMT-89 protocol is a safe regimen and is highly effective in advanced LL without bone marrow involvement and in patients with advanced Ann Arbor stage III–IV disease.
38
Intensive chemotherapy with mitoxantrone administered as a single injection in patients with high-risk acute myeloid leukemia: results of the EMA 2000 trial.
Xavier Thomas,Mohamed Elhamri,Youcef Chelghoum,Oumedaly Reman,Philippe Arnaud,Emmanuel Raffoux,Quoc-Hung Le,Emmanuelle Tavernier,Hervé Dombret,Mauricette Michallet +9 more
TL;DR: EMA chemotherapy using a single injection of mitoxantrone is effective in the treatment of high-risk AML in patients with refractory or relapsed acute myelogenous leukemia between October 2000 and December 2003.
10
Allogeneic H ematopoietic S tem-Cell T ransplantation A fter Nonmyeloablative P reparative R egimens: I mpact o f Pretransplantati on a nd P osttransplantat ion F actors on O utcome
Mauricette Michallet,Karin Bilger,Michel Attal,Anne Huyn,Didier Blaise,Philippe Moreau,Pierre Bordigoni,Mathieu Kuentz,A Sadoun,Jean-Yves Cahn,Xavier Thomas,Philippe Arnaud,Nicole Raus,Arnaud Pigneux,Jean-Michel Boiron +14 more
- 01 Jan 2001
TL;DR: Encouraging results from nonmyeloablative conditioning regimens before allotransplantation are shown and the impact of some pre- and posttransplantation factors on outcome after transplantation is demonstrated.
Effect of priming with granulocyte-macrophage colony-stimulating factor in younger adults with newly diagnosed acute myeloid leukemia: a trial by the Acute Leukemia French Association (ALFA) Group.
Xavier Thomas,Emmanuel Raffoux,S. de Botton,Cécile Pautas,Philippe Arnaud,T de Revel,Oumedaly Reman,Christine Terré,Bernadette Corront,C. Gardin,Quoc-Hung Le,B. Quesnel,Catherine Cordonnier,J. H. Bourhis,Mohamed El-Hamri,Pierre Fenaux,Claude Preudhomme,Mauricette Michallet,Sylvie Castaigne,Hervé Dombret +19 more
TL;DR: Priming of leukemic cells with hematopoietic growth factors is a means of enhancing the efficacy of chemotherapy in younger adults with AML as well as selecting patients with intermediate-risk cytogenetics for treatment with GM-CSF.